Disrupting the platelet internal membrane via PI3KC2α inhibition impairs thrombosis independently of canonical platelet activation
- 22 July 2020
- journal article
- research article
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 12 (553)
- https://doi.org/10.1126/scitranslmed.aar8430
Abstract
Arterial thrombosis causes heart attacks and most strokes and is the most common cause of death in the world. Platelets are the cells that form arterial thrombi, and antiplatelet drugs are the mainstay of heart attack and stroke prevention. Yet, current drugs have limited efficacy, preventing fewer than 25% of lethal cardiovascular events without clinically relevant effects on bleeding. The key limitation on the ability of all current drugs to impair thrombosis without causing bleeding is that they block global platelet activation, thereby indiscriminately preventing platelet function in hemostasis and thrombosis. Here, we identify an approach with the potential to overcome this limitation by preventing platelet function independently of canonical platelet activation and in a manner that appears specifically relevant in the setting of thrombosis. Genetic or pharmacological targeting of the class II phosphoinositide 3-kinase (PI3KC2α) dilates the internal membrane reserve of platelets but does not affect activation-dependent platelet function in standard tests. Despite this, inhibition of PI3KC2α is potently antithrombotic in human blood ex vivo and mice in vivo and does not affect hemostasis. Mechanistic studies reveal this antithrombotic effect to be the result of impaired platelet adhesion driven by pronounced hemodynamic shear stress gradients. These findings demonstrate an important role for PI3KC2α in regulating platelet structure and function via a membrane-dependent mechanism and suggest that drugs targeting the platelet internal membrane may be a suitable approach for antithrombotic therapies with an improved therapeutic window.Keywords
Funding Information
- Australian Research Council (FT130100540)
- National Health and Medical Research Council (1047295)
- Cass Foundation (SM16/7334)
This publication has 36 references indexed in Scilit:
- Transgenic, inducible RNAi in megakaryocytes and platelets in miceJournal of Thrombosis and Haemostasis, 2010
- A microfluidics device to monitor platelet aggregation dynamics in response to strain rate micro-gradients in flowing bloodLab on a Chip, 2009
- Microfluidic focal thrombosis model for measuring murine platelet deposition and stability: PAR4 signaling enhances shear‐resistance of platelet aggregatesJournal of Thrombosis and Haemostasis, 2008
- Taming the PI3K team to hold inflammation and cancer at bayPharmacology & Therapeutics, 2008
- Tissue-specific and reversible RNA interference in transgenic miceNature Genetics, 2007
- A critical role for the transcription factor Scl in platelet production during stress thrombopoiesisBlood, 2006
- A Pharmacological Map of the PI3-K Family Defines a Role for p110α in Insulin SignalingCell, 2006
- Characterization of the megakaryocyte demarcation membrane system and its role in thrombopoiesisBlood, 2006
- Probing tumor phenotypes using stable and regulated synthetic microRNA precursorsNature Genetics, 2005
- The identification of platelets and platelet antigens in histological sectionsThe Journal of Pathology and Bacteriology, 1965